NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage biotechnology company pioneering systems biology-driven therapeutics, announced data from its multi-regional, randomized, ...
NEW HAVEN, Conn and NEW YORK and SHANGHAI, April 08, 2022 (GLOBE NEWSWIRE) -- Yiviva and Yale scientists will present new data from Yiviva’s oncology portfolio at the 2022 American Association for ...
Patterns of failure and treatment for hepatocellular carcinoma after immune checkpoint inhibitors. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...
An experimental drug based on ancient Chinese herbal medicine can help ease the toxic side effects of chemotherapy and radiation therapy in cancer patients, the results of a small new trial results ...
The first patients have been dosed in a multi-regional Phase IIB randomized, placebo-controlled clinical trial for the treatment of hepatitis B-associated liver cancer. Being tested in the first line ...
A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results